Referred to the House Committee on Energy and Commerce.
This bill amends the Federal Food, Drug, and Cosmetic Act to create a uniform federal regulatory framework for pet food labels, labeling, advertising, and ingredient review. It preempts State and local requirements on pet food labels/advertising, deems many AAFCO-listed ingredients GRAS unless FDA finds otherwise, requires FDA review deadlines and guidance, permits certain marketing claims under defined conditions, delegates responsibility to the FDA Center for Veterinary Medicine, and mandates rulemaking adopting AAFCO model regulations within two years.
Preemption: liberals worry state protections lost; conservatives welcome uniformity
Relative to its intended legislative type, this bill is a substantive statutory reform that is generally well constructed: it amends the FD&C Act with clear definitions, preemption language, specific procedural deadlines, delegated responsibilities to CVM, and reporting requirements.
This bill amends the Federal Food, Drug, and Cosmetic Act to create a uniform federal regulatory framework for pet food labels, labeling, advertising, and ingredient review.
It preempts State and local requirements on pet food labels/advertising, deems many AAFCO-listed ingredients GRAS unless FDA finds otherwise, requires FDA review deadlines and guidance, permits certain marketing claims under defined conditions, delegates responsibility to the FDA Center for Veterinary Medicine, and mandates rulemaking adopting AAFCO model regulations within two years.
Moderate chance: narrow, technical reform helps industry and FDA clarity, but broad preemption and administrative implications raise opposition and Senate friction.
Relative to its intended legislative type, this bill is a substantive statutory reform that is generally well constructed: it amends the FD&C Act with clear definitions, preemption language, specific procedural deadlines, delegated responsibilities to CVM, and reporting requirements. It integrates with existing law by referencing CFR sections and the AAFCO publication and establishes measurable deadlines and accountability reports.
Preemption: liberals worry state protections lost; conservatives welcome uniformity
These are examples from the analysis, not a ranked list of the most-affected groups.
Preemption: liberals worry state protections lost; conservatives welcome uniformity
Skeptical of the bill’s broad federal preemption and automatic GRAS deeming.
Appreciates streamlined review and clearer definitions, but worries about reduced state authority, weaker consumer protections, and less transparency about ingredient safety.
Generally supportive of federal uniformity and clearer FDA responsibilities, while cautious about implementation details.
Wants assurances that FDA will have resources, that consumer protections remain strong, and that preemption is narrowly defined.
Favorable toward national uniform rules that reduce state-level regulatory burdens and expedite market access.
Views GRAS deeming, clear labeling rules, and deadlines as pro-business, supporting innovation and interstate commerce.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Moderate chance: narrow, technical reform helps industry and FDA clarity, but broad preemption and administrative implications raise opposition and Senate friction.
The bill has not accumulated any surfaced votes yet.
Preemption: liberals worry state protections lost; conservatives welcome uniformity
Moderate chance: narrow, technical reform helps industry and FDA clarity, but broad preemption and administrative implications raise opposi…
Relative to its intended legislative type, this bill is a substantive statutory reform that is generally well constructed: it amends the FD&C Act with clear definitions, preemption language, specific procedural deadline…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.